CATHY SEIBEL, District Judge.
Before the Court are Defendants' Motions to Dismiss the 31 member cases in the caption pursuant to Case Management Order No. ("CMO") 22A, (13-MD-2434, Doc. 1510). Under CMO 22A, Defendants are permitted to submit a letter explaining why each case should be dismissed consistent with this Court's opinion in Truitt v. Bayer, No. 13-CV-7811, 2014 WL 2971179 (S.D.N.Y. July 2, 2014). Each Plaintiff against whom Defendants so move must then either voluntarily dismiss her case with prejudice or set forth the specific facts and/or law that distinguish her case from Ms. Truitt's. Despite the number of individual member cases that Defendants have moved to dismiss, Defendants' motions implicate only four discrete sets of issues, and each case fits into one of these four groups.
The parties' familiarity with the procedural history of this multi-district litigation ("MDL") — including the discussion of fact and law in Truitt, which is hereby incorporated — and the facts alleged in each individual member case is presumed.
"To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to `state a claim to relief that is plausible on its face.'" Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). "A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Id. "While a complaint attacked by a Rule 12(b)(6) motion to dismiss does not need detailed factual allegations, a plaintiff's obligation to provide the grounds of his entitlement to relief requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do." Twombly, 550 U.S. at 555 (alteration, citations, and internal quotation marks omitted). While Federal Rule of Civil Procedure 8 "marks a notable and generous departure from the hyper-technical, code-pleading regime of a prior era, . . . it does not unlock the doors of discovery for a plaintiff armed with nothing more than conclusions." Iqbal, 556 U.S. at 678-79.
In considering whether a complaint states a claim upon which relief can be granted, the court "begin[s] by identifying pleadings that, because they are no more than conclusions, are not entitled to the assumption of truth," and then determines whether the remaining well-pleaded factual allegations, accepted as true, "plausibly give rise to an entitlement to relief." Id. at 679. Deciding whether a complaint states a plausible claim for relief is "a context-specific task that requires the reviewing court to draw on its judicial experience and common sense." Id. "[W]here the well-pleaded facts do not permit the court to infer more than the mere possibility of misconduct, the complaint has alleged — but it has not `shown' — `that the pleader is entitled to relief.'" Id. (alteration omitted) (quoting Fed. R. Civ. P. 8(a)(2)).
A defendant may raise a statute of limitations defense in a Rule 12(b)(6) motion to dismiss. Gelber v. Stryker Corp., 788 F.Supp.2d 145, 153 (S.D.N.Y. 2011) (citing Ghartey v. St. John's Queens Hosp., 869 F.2d 160, 162 (2d Cir. 1989)).
Leave to amend a complaint should be freely given "when justice so requires." Fed. R. Civ. P. 15(a)(2). It is "within the sound discretion of the district court to grant or deny leave to amend." McCarthy v. Dun & Bradstreet Corp., 482 F.3d 184, 200 (2d Cir. 2007). "Leave to amend, though liberally granted, may properly be denied for: `undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to cure deficiencies by amendments previously allowed, undue prejudice to the opposing party by virtue of allowance of the amendment, futility of amendment, etc.'" Ruotolo v. City of N.Y., 514 F.3d 184, 191 (2d Cir. 2008) (quoting Foman v. Davis, 371 U.S. 178, 182 (1962)). Further, a plaintiff need not be given leave to amend if she fails to specify how amendment would cure the pleading deficiencies in her complaint. See TechnoMarine SA v. Giftports, Inc., 758 F.3d 493, 505 (2d Cir. 2014); see also Gallop v. Cheney, 642 F.3d 364, 369 (2d Cir. 2011) (district court did not err in dismissing claim with prejudice in absence of any indication plaintiff could or would provide additional allegations leading to different result).
The twelve Louisiana Plaintiffs submitted substantively identical oppositions to Defendants' motions to dismiss, contending that their claims are timely under Louisiana's one-year prescription period for products liability claims, La. Civ. Code Ann. Art. § 3492, and Louisiana's version of the discovery rule.
Nevertheless, even considering the substance of the Louisiana Plaintiffs' argument, it is clear that Louisiana's discovery rule does not render their claims timely. Louisiana's discovery rule delays the running of the prescription period until "the injured party discovers or should have discovered the facts upon which [her] cause of action is based." Wimberly v. Gatch, 635 So.2d 206, 211 (La. 1994). Under this rule, which is strictly construed, Terrebonne Parish Sch. Bd. v. Columbia Gulf Transmission Co., 290 F.3d 303, 320 (5th Cir. 2002),
Stuart v. Am. Cyanamid Co., 158 F.3d 622, 630 (2d Cir. 1998) (internal quotation marks and citations omitted) (applying Louisiana law). Thus, the time to sue begins to run when a plaintiff has a reasonable basis to pursue a claim against a specific defendant. Terrebonne, 290 F.3d at 320.
Louisiana Plaintiffs argue that, on a Fed. R. Civ. P. 12(b)(6) motion, the Court cannot determine when the statute of limitations began to run, because discovery is needed to determine when each Plaintiff knew that Mirena was at fault for her injuries. (See Hingle Letter 2; Berger Letter 2.) Under Louisiana law, however, it is Plaintiff's burden to demonstrate the timeliness of a facially time-barred claim, see Mungovan v. CitiMortgage, Inc., No. 12-CV-616, 2013 WL 3783982, at *2 (E.D. La. July 18, 2013), and under federal law it is her burden to allege facts plausibly suggesting she can do so, see George, 2014 WL 1259613, at *2; see also Angiulo v. Cnty. of Westchester, No. 11-CV-7823, 2012 WL 5278523, at *3 n.4 (S.D.N.Y. Oct. 25, 2012) (under Iqbal, "a plausible claim must come before discovery, not the other way around") (emphasis in original). Moreover, putting burdens aside, each of the Louisiana Plaintiffs alleges (as in Truitt) that she underwent an operation to remove the Mirena from an area of the body where it was not supposed to be — either outside of or embedded in the uterus.
The Louisiana Plaintiffs' cases are thus properly dismissed on a Fed. R. Civ. P. 12(b)(6) motion. See Clement, 914 F. Supp. 2d at 369. Moreover, because they neither request permission to file amended complaints nor suggest that they possess facts that could cure the defects identified above, their claims are dismissed with prejudice. See Gallop, 642 F.3d at 369.
The seventeen California Plaintiffs — each of whom is represented by Kabateck, Brown, Kellner, LLP — filed suit in California even though their Mirenas were inserted and removed in other states, and even though they were not California residents at the time of insertion or removal.
Each of these diversity cases was filed in California. Accordingly, California's choice-of-law rules apply. See Menowitz, 991 F.2d at 40; see also In re Zyprexa Prods. Liab. Litig., No. 04-MD-1596, 2009 WL 5062114, at *11 (E.D.N.Y. Dec. 10, 2009) (applying California's choice-of-law rules to MDL member case filed in California), aff'd sub nom. Guillen v. Eli Lilly & Co., 394 F. App'x 814 (2d Cir. 2010) (summary order).
"California applies the governmental interest approach to conflict of law issues." Deutsch v. Turner Corp., 324 F.3d 692, 716 (9th Cir. 2003) (internal quotation marks omitted). The governmental interest approach consists of three steps:
McCann v. Foster Wheeler LLC, 225 P.3d 516, 527 (Cal. 2010) (internal quotation marks omitted).
The parties agree that California's two-year statute of limitations is shorter than the statutes of limitations of the states in which the California Plaintiffs' Mirenas were inserted and/or removed. These statutes thus differ, and the issue becomes whether the foreign states possess an interest in having their statutes of limitations for products liability claims apply to California Plaintiffs' cases and, if they do possess such an interest, whether the foreign states' interest outweighs California's interest in having its shorter statute of limitations applied. In conducting this analysis, the Court must examine each state's interest in having the particular law at issue (here, the statute of limitations), rather than its laws in general, applied to the case. See id. at 527-32.
California jurisprudence makes clear that "[s]tatutes of limitation are designed to protect the enacting state's residents and courts from the burdens associated with the prosecution of stale cases in which memories have faded and evidence has been lost." Ashland Chem. Co. v. Provence, 181 Cal.Rptr. 340, 341 (Cal. Ct. App. 1982). Accordingly,
Deutsch, 324 F.3d at 716-17.
Because California Plaintiffs have not presented evidence of such extraordinary interests,
Despite the authority cited above, California Plaintiffs contend that
(E.g., 14-CV-5229, Doc. 9, at 2.)
California Plaintiffs' first three arguments are entirely without merit. Their attorneys filed their cases in California district courts (for no reason the Court can discern other than their California-based attorneys' convenience), which under clear Second Circuit precedent (which California Plaintiffs knew would apply given that this MDL had been consolidated in this Court before they filed their lawsuits) rendered California the forum state even after transfer to this MDL. See Menowitz, 991 F.2d at 40; see also IBLC Abogados, S.C. v. Bracamonte, No. 11-CV-2380, 2013 WL 3829401, at *11 (S.D. Cal. July 23, 2013) ("Plaintiff chose the California court understanding that that action would be taken into account in favor of applying California law.").
California Plaintiffs' final contention (that California's interest in applying its statute of limitations is at its nadir because there are no California parties) is unavailing for the reasons stated above — i.e. even absent any California party, California still has a "substantial interest in preventing the prosecution in its courts of claims which it deems to be stale." Deutsch, 324 F.3d at 717 (internal quotation marks omitted). This substantial interest outweighs the foreign state's interest in having its longer statute of limitations apply unless the plaintiff can show that the foreign state has an "extraordinary interest" beyond the mere fact that claims would be timely if its law applied. See Theranos, 876 F. Supp. 2d at 1131.
Accordingly, California's statute of limitations and discovery rule apply to California Plaintiffs' claims.
California Plaintiffs next contend that, even if California law applies, California's discovery rule is distinguishable from the discovery rules of Texas and Indiana that were discussed in Truitt, because "the California discovery rule tolls accrual until the plaintiff `is aware of her injury and its negligent cause.'" (14-CV-5229, Doc. 9, at 3 (quoting Jolly v. Eli Lilly & Co., 751 P.2d 923, 927 (Cal. 1988)) (emphasis in Doc. 9).) Thus, according to California Plaintiffs, the statute of limitations was not triggered until they had "specific knowledge and understanding of the defect of the Mirena." (Id. (citing Fox v. Ethicon Endo-Surgery, Inc., 110 P.3d 914 (Cal. 2005)).)
California Plaintiffs misinterpret Fox,
Based on the foregoing, California Plaintiffs' assertion that California's discovery rule differs from the discovery rules of Texas and Indiana in that California's statute of limitations does not begin to run until a plaintiff has "specific knowledge and understanding of the defect of the Mirena," (e.g., 14-CV-5229, Doc. 9, at 3), is incorrect. Because California Plaintiffs do not argue that their factual allegations differ in any significant way from those made by Ms. Truitt,
Finally, California Plaintiffs argue that Defendants "should be judicially estopped from asserting that California's statute of limitations applies to [their] claims because it is entirely inconsistent with its earlier position that the multi-plaintiff action filing in California was improper." (E.g., 14-CV-5229, Doc. 9, at 3.) This argument borders on the frivolous. In the conference to which California Plaintiffs refer, Defendants stated — correctly — that multi-plaintiff complaints were improperly joined because they include "[c]ompletely different facts and [the] claims do not arise out of the same transaction or occurrence" under Fed. R. Civ. P. 20, not that these cases were improperly filed in California. (E.g., id. Ex. A, at 41.) Accordingly, Defendants have not maintained inconsistent positions and judicial estoppel does not apply. See Wight v. BankAmerica Corp., 219 F.3d 79, 90 (2d Cir. 2000) ("A party invoking judicial estoppel must show that: (1) his adversary advanced an inconsistent factual position in a prior proceeding, and (2) the prior inconsistent position was adopted by the first court in some manner.") (internal quotation marks omitted).
The Court regrets this outcome. The California Plaintiffs' claims will not be tested on the merits because of a poor choice by their counsel as to where to file. California Plaintiffs' counsel is directed to provide a copy of this Opinion and Order to their affected clients.
Oklahoma law applies to Ms. Fitzgerald's claims, because she filed her suit in Oklahoma. See Menowitz, 991 F.2d at 40. Ms. Fitzgerald's complaint states:
Defendants argue that Ms. Fitzgerald's products liability claims are time-barred under Oklahoma's two-year statute of limitations. See Okla. Stat. tit. 12, § 95(A)(3).
Fatal to Ms. Fitzgerald's argument, her complaint does not plead any factual allegations regarding the state court action, nor are any state court documents attached to the complaint (or, for that matter, her motion papers) as exhibits. Oklahoma's savings statute thus does not render Ms. Fitzgerald's claims timely. See Hagy v. Am. Honda Motor Co., 125 F.Supp.2d 456, 458 (W.D. Okla. 2000) ("Under Oklahoma law, plaintiffs bear the burden of pleading sufficient facts to demonstrate that their claims are not time-barred, and when they rely on the savings statute to preserve claims, they must include factual allegations concerning the filing and pendency of a prior, timely suit.") (citing Kelley v. Lowder's Heirs, 243 P.2d 1006, 1008 (Okla. 1952)).
Although such a technical pleading deficiency could be cured by amendment, Ms. Fitzgerald's Plaintiff Fact Sheet ("PFS") shows that any amendment would be futile because her state court case was not timely filed within the two-year statute of limitations. See Gallop, 642 F.3d at 369. Ms. Fitzgerald checked the "yes" box in response to the question, "Has any healthcare provider told you . . . that this/these claimed physical injury(ies) was/were related to your use of Mirena?" (14-CV-2572, Doc. 26, Ex. 1, at 22.) Underneath this box, Ms. Fitzgerald wrote that on March 17, 2011, her doctor "called [her] and told [her she] need[ed] surgery to remove Mirena because it perforated [her] uterine wall and migrated." (Id.) Accordingly, the two-year statute of limitations was triggered on that date, not on the date the device was surgically removed. See Schrock v. Wyeth, Inc., 727 F.3d 1273 (10th Cir. 2013) (under Oklahoma's discovery rule, "`the statute of limitations in product liability cases does not begin to run until the plaintiff knows, or as a reasonably prudent person should know, that he has the condition for which his action is brought, and that the defendant caused it'") (quoting Daugherty v. Farmers Co-op. Ass'n, 689 P.2d 947, 950 (Okla. 1984)); see also Truitt, 2014 WL 2971179, at *7 ("When the plaintiff knows that the IUD is no longer in the uterus and has to be removed from wherever it has migrated, the conclusion that the statute of limitations is triggered seems unavoidable."). Ms. Fitzgerald filed her case in state court on April 1, 2013, over two years after March 17, 2011. Ms. Fitzgerald thus does not possess facts from which she could plead a timely claim, see Okla. Stat. tit. 12, § 100 (original action must be "commenced within due time"), and her case is dismissed with prejudice.
Ohio law applies to Ms. Wojtowicz's claims, because she filed her suit in Ohio. See Menowitz, 991 F.2d at 40. Ms. Wojtowicz's amended complaint states:
(13-CV-4693, Doc. 55, at ¶ 60.) Ms. Wojtowicz filed her original complaint on March 29, 2013. (See id., Doc. 1.)
Defendants contend that Ms. Wojtowicz's products liability claims are time-barred under Ohio's two-year statute of limitations, see Ohio Rev. Code Ann. § 2305.10(A), which began to run in June 2010.
The letter to which Ms. Wojtowicz refers is four paragraphs long. (See 13-CV-4693, Doc. 75, Ex. 1.) It is in response to Ms. Wojtowicz's request that Defendants reimburse her for the cost of having her Mirena "checked and removed." (Id. Ex. 2.) Defendants' letter states, in relevant part,
(Id. Ex. 1 (emphasis in original).)
Under Ohio law, "[a] prima facie case for equitable estoppel requires a plaintiff to prove four elements: (1) that the defendant made a factual misrepresentation; (2) that it is misleading; (3) that it induced actual reliance which is reasonable and in good faith; and (4) that the reliance caused detriment to the relying party." JRC Holdings, Inc. v. Samsel Servs. Co., 850 N.E.2d 773, 779 (Ohio Ct. App. 2006) (internal quotation marks and alterations omitted). "Ohio cases have held that when applied to a limitations defense, a plaintiff [seeking application of equitable estoppel] must show that the defendant misrepresented the length of the limitations period, promised a better settlement if the plaintiff did not bring suit, or made similar representations to induce a delay in bringing suit." Allen v. Andersen Windows, Inc., 913 F.Supp.2d 490, 510 (S.D. Ohio 2012) (citing JRC Holdings, 850 N.E.2d at 779). "A court may resolve the issue of equitable estoppel's applicability on a Rule 12(b)(6) motion to dismiss if the plaintiff has not pleaded facts that, if proved, demonstrate the defendant's efforts to prevent the plaintiff from filing suit." Id.; see Walburn v. Lockheed Martin Util. Servs., Inc., 443 F. App'x 43, 47 (6th Cir. 2011) (under Ohio law, "[t]he party relying on equitable estoppel bears the burden to establish that the requirements for equitable estoppel have been met").
Equitable estoppel does not apply to Ms. Wojtowicz's claims. First, Ms. Wojtowicz did not plead facts regarding the letter — i.e. the facts she claims are relevant to her equitable estoppel argument. See Allen, 913 F. Supp. 2d at 510. Second, any amendment of her complaint would be futile, see Gallop, 642 F.3d at 369, because the letter from Defendants is not misleading as to the length of the statute of limitations or Defendants' intention to settle Ms. Wojtowicz's claim if she would forgo a lawsuit, see Walburn, 443 F. App'x at 49 (equitable estoppel did not apply to misrepresentations that "did not pertain to the limitations period, defendant's willingness to waive the [limitations] defense, or an inducement to plaintiffs to abandon the presumably timely action"). Rather, the letter is a straightforward denial of responsibility for Ms. Wojtowicz's injuries and claims that she was adequately warned. Even if false, these statements are not the types of misrepresentation that could support an equitable estoppel argument. See Young v. Carrier Corp., No. 14-CV-974, 2014 WL 6617650, at *6 (N.D. Ohio Nov. 21, 2014) (equitable estoppel did not save time-barred claims because, "[w]hile Plaintiff alleges that Defendant concealed the alleged defect, and that Carrier misrepresented the cause of her problems, there is no allegation that Defendant said anything calculated to induce [her] to forgo the right to sue") (internal quotation marks and citations omitted); Kegg v. Mansfield, No. 2000-CA-311, 2001 WL 474264, at *5 (Ohio Ct. App. Apr. 30, 2001) (equitable estoppel does not bar statute of limitations defense where alleged misrepresentations went to merits of claim, not to limitations period or proposed settlement). Accordingly, Ms. Wojtowicz's claims are dismissed with prejudice.
For the foregoing reasons, Plaintiffs' claims are dismissed with prejudice. The Clerk of Court is respectfully requested to spread this Opinion and Order to, and close, the cases in the caption. The Clerk of Court is further requested to terminate all pending motions in the cases in the caption, and the following pending motions in 13-MD-2434: Docs. 1834, 1837, 1839, 1841, 1843-1845, 1847, 1848, 1850, 1851, 1853-1858.
Also unhelpful to Louisiana Plaintiffs is Sanchez v. Bos. Scientific Corp., No. 12-CV-5762, 2014 WL 202787 (S.D. W. Va. Jan. 17, 2014), a case the Hingle Letter cites (by merely providing the docket number, not a citation to an online database) for the proposition that the Louisiana Plaintiffs did not know enough about the link between Mirena and their injuries when the Mirena was removed to trigger the prescription period, (see Hingle Letter 2). Sanchez held that the statute of limitations for a suit against the manufacturer of vaginal mesh was not triggered by repeated doctor visits and surgeries to relieve irritation caused by vaginal mesh. Sanchez is inapposite to Louisiana Plaintiffs' cases because, first, it applied California law, not Louisiana law. See Sanchez, 2014 WL 202787, at *5. Second, the facts of Sanchez are distinguishable. In Sanchez, the plaintiff's doctors indicated that the irritation was caused by the plaintiff's body, not the vaginal mesh. See id. at *2, 7-8 (where physician told plaintiff "she had `no idea why this was happening and for some reason [plaintiff's] body did not like' the mesh products," there was a question of fact whether plaintiff reasonably believed "the cause of her symptoms were related to her body's rejection of the mesh" rather than a defect with the mesh). Here, for the reasons stated in Truitt, it was obvious that the Mirena device was not functioning as intended; there was a clear link between Mirena and the Louisiana Plaintiffs' injuries; and Louisiana Plaintiffs neither pleaded nor provided in their opposition letters any facts as to plausible alternative explanations for their injuries that would have dissuaded a reasonable individual from inquiring into the link between her injuries and the Mirena that perforated or embedded in her uterus.